Fischer Medical Ventures Adjusts Quality Grade Amid Strong Sales Growth and Market Resilience
Fischer Medical Ventures has recently seen a change in its quality grade, now rated as average. The company has experienced significant sales growth over five years, though EBIT growth has been modest. Its favorable debt management contrasts with challenges in profitability, while it has consistently outperformed the BSE 500 index.
Fischer Medical Ventures, a midcap player in the commodity chemicals industry, has recently undergone an adjustment in evaluation, reflecting a change in its quality grade from below average to average. This revision comes amid a backdrop of notable financial metrics that highlight the company's performance.Over the past five years, Fischer Medical has demonstrated significant sales growth of 427.60%, although its EBIT growth has been modest at 0.60%. The company's debt management appears favorable, with a debt to EBITDA ratio of 0.85 and a net debt to equity ratio of 0.00%, indicating a low reliance on debt financing. However, the return on equity (ROE) stands at 2.29%, suggesting challenges in generating profitability relative to shareholders' funds.
In terms of market performance, Fischer Medical has outperformed the BSE 500 index consistently over the last three years, achieving a remarkable return of 1533.99%. Despite a flat financial performance in the latest quarter, the stock has shown resilience with a 55.21% return over the past year.
Overall, the adjustment in evaluation reflects the company's evolving financial landscape and market position.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
